Biotech News

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

Kura Oncology (KURA)Kura Oncology2026-06-25 13:46 ESTClinical readout

– Regulatory Filing in Japan Planned Following Clinical Trial Completion – TOKYO and SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced the first patient has been dosed in a Japanese Phase 2

Open original release

Related news

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology Reports First Quarter 2026 Financial Results

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

KURAKura Oncology2026-06-25 13:46 EST

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

View all latest news

Kura Oncology

Kura Oncology is an oncology-focused biopharmaceutical company centered on cancer programs, with investors watching clinical data, regulatory milestones, and the commercial path for its lead assets.

Recent company news

KURAKura Oncology2026-06-26 09:54 EST

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

KURAKura Oncology2026-06-26 09:54 EST

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

KURAKura Oncology2026-06-26 09:54 EST

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

KURAKura Oncology2026-06-26 09:54 EST

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

KURAKura Oncology2026-06-26 09:54 EST

Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States